SOUTH SAN FRANCISCO, CA, USA I October 16, 2023 I Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023.

Presentation Details:

  • Development of Next Generation ADCs Using Novel Expression Platforms & Precise Conjugation
    • Presenter: Gang Yin
    • Date/Time: October 17, 2023, 12:00pm PT
  • Discovery of Novel Linker Payloads for Site-Specific ADCs with Improved Efficacy & Therapeutic Index
    • Presenter: Krishna Bajjuri
    • Date/Time: October 17, 2023, 2:00pm PT
  • Precision Engineering for Enhanced Therapeutic Index: Designing STRO-004, a Tissue Factor Targeted ADC for Broadened Efficacy & Safety
    • Presenter: Alice Yam
    • Date/Time: October 17, 2023, 5:30pm PT
  • Stress Free ADC Production with Cell-Free Technology
    • Presenter: Ganesh Vissvesvaran
    • Date/Time: October 18, 2023, 12:00pm PT
  • Preclinical Development of STRO-003, a ROR1 Targeting Antibody-Drug Conjugate for Treatment of Hematologic & Solid Cancers
    • Presenter: Helena Kiefel
    • Date/Time: October 18, 2023, 2:00pm PT

Poster Details:

  • Site-specific Dual Conjugation Enabled by an Integrated in vivo / in vitro Antibody Production Platform
    • Presenter: Miao Wen
    • Date/Time: October 17, 2023, 6:00pm PT

Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit

SOURCE: Sutro Biopharma